NodThera Alternatives & Competitors
12 companies similar to NodThera — Treating chronic disease by targeting inflammation at its source
Companies similar to NodThera
Azome Therapeutics
Developing selective NLRP3 inflammasome inhibitors for severe inflammatory diseases
Upstream Bio
Developing treatments for inflammatory diseases
Waltham, United States
BIORCHESTRA Co., Ltd.
We develop novel RNA-based therapeutics that will be able to bring about a paradigm shift...
Cambridge, United States
Inflazome
Inflazome develops drugs to block inflammasome signals, reducing unwanted inflammation ass...
Rival Readout
Competing with NodThera? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Invirsa, Inc
A Phase 3 ready clinical-stage ophthalmology company pioneering the world's first DNA Repa...
Columbus, United States
Tridek-One
We develop first-in-class CD31 checkpoint agonists for the treatment of auto-immune diseas...
Paris, France
LIPUM AB
We have developed a biological drug SOL-116 for treatment of chronic inflammatory diseases
Umea, Sweden
Olatec Therapeutics
Leading the Development of Specific NLRP3 Antagonists, Mediator of Innate Inflammatory Re...
New York, United States
Emalex Biosciences
Improving people's lives impacted by central nervous system disorders through meaningful s...
Chicago, United States
Tvardi Therapeutics
Breakthrough Medicines for Cancer, Chronic Inflammation & Fibrosis
Houston, United States
BioAge Labs
We are harnessing the biology of human aging to develop novel targets and therapies for me...
Emeryville, United States
ImmunOs Therapeutics AG
Novel human immunomodulatory proteins for cancer and autoimmune diseases with a specific r...
Schlieren, Switzerland
About NodThera
NodThera, founded in 2016, is carving a niche within the Biotechnology, Health Care, and Life Sciences sectors. The company's groundbreaking work focuses on developing a novel class of potent and highly selective NLRP3 inflammasome inhibitors, potentially revolutionizing the treatment of chronic inflammation-driven dis...
Development of NLRP3 inhibitors, Clinical research and trials, Pharmaceutical innovation
Individuals with age-related diseases, Patients with cardiometabolic disorders, Patients with neuroinflammatory conditions, Healthcare providers
Biotech, Inflammasome Research, Chronic Inflammation Treatment, NLRP3 Inhibitors, Neuroinflammatory Diseases, Immunotherapy, Drug Development, Innate Immune System, Cambridge, Seattle, Boston, UK, USA, Pharmaceuticals
B2B, B2B2C
Product Sales, Licensing
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around NodThera: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at NodThera on 11 Sep 2024. The 12 companies listed here were last checked between 11 Sep 2024 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
